BoomRay Pharmaceuticals, a China‑based clinical‑stage biotechnology company and specialist in radionuclide drug conjugates (RDCs), announced that it has entered into an exclusive global license agreement with Novartis (NYSE: NVS) for a preclinical radioligand therapy, with BoomRay eligible to receive up to USD 900 million in total deal value plus royalties on future global net sales.
Deal Snapshot
| Item | Detail |
|---|---|
| Licensor | BoomRay Pharmaceuticals (private, clinical-stage, Suzhou, China) |
| Licensee | Novartis (NYSE: NVS) |
| Asset | Preclinical radioligand therapy |
| Structure | Exclusive global license agreement |
| Total Deal Value | Up to USD 900 million |
| Payment Components | Upfront payment + development, regulatory, and sales milestone payments – individual amounts not disclosed |
| Royalties | Royalties on future global net sales – rate not disclosed |
| Announcement Date | 22 Sep 2026 |
Company & Platform Profile – BoomRay
- Modality Focus: A clinical‑stage biotechnology company focused on developing novel radiopharmaceutical conjugates for precision tumor diagnosis and treatment.
- End‑to‑End Capabilities: Deep radiopharmaceutical expertise spanning drug discovery, radiochemistry, and clinical translation, enabling in‑house advancement from target selection to the clinic.
- Pipeline Ambition: BoomRay is accelerating development of its proprietary radiopharmaceutical conjugate pipeline with “first‑in‑class” or “best‑in‑class” potential.
- Asset Details: The specific target, radioisotope payload, and indication of the licensed preclinical radioligand therapy – not disclosed.
Strategic Rationale
- Novartis’ Radioligand Leadership: The deal extends Novartis’ position as the global leader in radioligand therapy – the franchise behind Pluvicto and Lutathera – by adding a preclinical asset sourced from China’s fast‑maturing RDC ecosystem.
- Early‑Stage Optionality: Licensing at the preclinical stage gives Novartis early access at a comparatively low upfront cost, with the majority of the USD 900 million value contingent on development, regulatory, and commercial success.
- Platform Validation for BoomRay: An exclusive global license from a top‑tier multinational validates BoomRay’s end‑to‑end RDC platform and creates a funding engine to advance its remaining proprietary pipeline.
- China RDC Out‑Licensing Wave: The transaction reinforces the trend of Chinese radiopharmaceutical innovators monetizing discovery assets through global partnerships with Big Pharma licensees.
Market Impact & Outlook
- Radioligand Therapy Momentum: Global interest in targeted radionuclide oncology continues to intensify, driven by the commercial success of approved radioligand therapies and an expanding pipeline of alpha‑ and beta‑emitting conjugates.
- Milestone Economics: BoomRay’s up to USD 900 million biobucks package – combining upfront, development, regulatory, and sales milestones – ranks among the significant out‑licensing deals for China‑originated RDC assets.
- Pipeline Catalyst: Royalty entitlement on future global net sales provides BoomRay with long‑term economics beyond the license, aligned to Novartis’ clinical progression of the asset.
- Next Steps: IND‑enabling studies, first‑in‑human trial timing, and any expansion of the collaboration – not disclosed; program milestones will be the key catalysts to watch.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding preclinical development, clinical trial progression, milestone achievement, and commercial potential of the licensed radioligand therapy. Actual results may differ materially due to risks including discovery attrition, regulatory determinations, and competitive dynamics in the radioligand therapy field.-Fineline Info & Tech
